Confirmed efficacy of etoposide and dexamethasone in HLH treatment: Long-Term results of the cooperative HLH-2004 study

Blood

Volumn 130, Issue 25, 2017, Pages 2728-2738

  Bergsten, Elisabet ^a,b   Horne, AnnaCarin ^a,b   Aricó, Maurizio ^c   Astigarraga, Itziar ^d   Egeler, R Maarten ^e   Filipovich, Alexandra H ^f   Ishii, Eiichi ^g   Janka, Gritta ^h   Ladisch, Stephan ⁱ   Lehmberg, Kai ^h   Mcclain, Kenneth L ^j   Minkov, Milen ^k   Montgomery, Scott ^a,l,m   Nanduri, Vasanta ⁿ   Rosso, Diego ^o,p,q,r   Henter, Jan Inge ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Direzione Generale   (Italy)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁱ CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l ÖREBRO UNIVERSITY   (Sweden)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁿ WATFORD GENERAL HOSPITAL   (United Kingdom)

^o HOSPITAL GENERAL DE NIÑOS PEDRO DE ELIZALDE   (Argentina)

^p HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^q UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^r Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DEXAMETHASONE; ETOPOSIDE; PRF1 PROTEIN; PROTEIN; STX11 PROTEIN; STXBP2 PROTEIN; UNC13D PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYCLOSPORINE;

ACUTE MYELOID LEUKEMIA; ADULT; ARTICLE; CARDIAC HYPERTENSION; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIBLING; SURVIVAL RATE; SYSTEMIC THERAPY; INFANT; LONGITUDINAL STUDY; PROCEDURES; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOSPORINE; DEXAMETHASONE; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LONGITUDINAL STUDIES; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; TREATMENT OUTCOME;

EID: 85039156751     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-06-788349     Document Type: Article

References (57)

1. Janka GE. Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr. 1983;140(3): 221-230.
2. Emile JF, Abla O, Fraitag S, et al; Histiocyte Society. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22): 2672-2681.
3. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286(5446):1957-1959.
4. Feldmann J, Callebaut I, Raposo G, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003;115(4):461-473.
5. Ĉote M, Menager MM, Burgess A, et al. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J Clin Invest. 2009;119(12):3765-3773.
6. Zur Stadt U, Rohr J, Seifert W, et al. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. Am J Hum Genet. 2009;85(4):482-492.
7. Demirkol D, Yildizdas D, Bayrakci B, et al; Turkish Secondary HLH/MAS Critical Care Study Group. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: What is the treatment? Crit Care. 2012;16(2):R52.
8. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014; 383(9927):1503-1516.
9. Cetica V, Sieni E, Pende D, et al. Genetic predisposition to hemophagocytic lymphohistiocytosis: Report on 500 patients from the Italian registry. J Allergy Clin Immunol. 2016; 137(1):188-196.e4.
10. Henter JI, Ehrnst A, Andersson J, Elinder G. Familial hemophagocytic lymphohistiocytosis and viral infections. Acta Paediatr. 1993;82(4): 369-372.
11. Henter JI, Horne A, Arićo M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
12. Henter JI, Arico M, Egeler RM, et al. HLH-94: A treatment protocol for hemophagocytic lymphohistiocytosis. HLH study group of the Histiocyte Society. Med Pediatr Oncol. 1997; 28(5):342-347.
13. Ost A, Nilsson-Ardnor S, Henter JI. Autopsy findings in 27 children with haemophagocytic lymphohistiocytosis. Histopathology. 1998;32(4): 310-316.
14. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr. 2007;166(2): 95-109.
15. Horne A, Trottestam H, Aricò M, et al; Histiocyte Society. Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. Br J Haematol. 2008;140(3):327-335.
16. Deiva K, Mahlaoui N, Beaudonnet F, et al. CNS involvement at the onset of primary hemophagocytic lymphohistiocytosis. Neurology. 2012;78(15):1150-1156.
17. Fischer A, Cerf-Bensussan N, Blanche S, et al. Allogeneic bone marrow transplantation for erythrophagocytic lymphohistiocytosis. J Pediatr. 1986;108(2):267-270.
18. Jabado N, de Graeff-Meeder ER, Cavazzana- Calvo M, et al. Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors. Blood. 1997;90(12): 4743-4748.
19. Dürken M, Horstmann M, Bieling P, et al. Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: A single-centre experience of 12 patients. Br J Haematol. 1999;106(4): 1052-1058.
20. Kawa K, Sawada A, Sato M, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transplant. 2011;46(1):77-83.
21. Fujiwara S, Kimura H, Imadome K, et al. Current research on chronic active Epstein-Barr virus infection in Japan. Pediatr Int. 2014;56(2): 159-166.
22. Stéphan JL, Donadieu J, Ledeist F, Blanche S, Griscelli C, Fischer A. Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids, and cyclosporin Blood. 1993;82(8):2319-2323.
23. Imashuku S, Hibi S, Ohara T, et al; Histiocyte Society. Effective control of Epstein-Barr virusrelated hemophagocytic lymphohistiocytosis with immunochemotherapy. Blood. 1999;93(6): 1869-1874.
24. Henter JI, Samuelsson-Horne A, Arico M, et al; Histocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7): 2367-2373.
25. Mahlaoui N, Ouachee-Chardin M, de Saint Basile G, et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: A single-center retrospective report of 38 patients. Pediatrics. 2007;120(3):e622-e628.
26. Trottestam H, Horne A, Arico M, et al; Histiocyte Society. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-Term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4577-4584.
27. Aricò M, Janka G, Fischer A, et al; FHL Study Group of the Histiocyte Society. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. Leukemia. 1996;10(2): 197-203.
28. Horne A, Janka G, Maarten Egeler R, et al; Histiocyte Society. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol. 2005;129(5): 622-630.
29. Trottestam H, Beutel K, Meeths M, et al. Treatment of the X-linked lymphoproliferative, Griscelli and Chediak-Higashi syndromes by HLH directed therapy. Pediatr Blood Cancer. 2009; 52(2):268-272.
30. Kalman VK, Klimpel GR. Cyclosporin A inhibits the production of gamma interferon (IFN gamma), but does not inhibit production of virus-induced IFN alpha/beta. Cell Immunol. 1983;78(1): 122-129.
31. Imashuku S, Hibi S, Kuriyama K, et al. Management of severe neutropenia with cyclosporin during initial treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis. Leuk Lymphoma. 2000;36(3-4):339-346.
32. Cooper N, Rao K, Gilmour K, et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood. 2006;107(3):1233-1236.
33. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
34. Zur Stadt U, Beutel K, Weber B, Kabisch H, Schneppenheim R, Janka G. A91V is a polymorphism in the perforin gene not causative of an FHLH phenotype. Blood. 2004;104(6): 1909-1910.
35. Henter JI, Elinder G, Finkel Y, Soder O. Successful induction with chemotherapy including teniposide in familial erythrophagocytic lymphohistiocytosis. Lancet. 1986;2(8520):1402.
36. Henter JI, Elinder G. Familial hemophagocytic lymphohistiocytosis. Clinical review based on the findings in seven children. Acta Paediatr Scand. 1991;80(3):269-277.
37. Thompson PA, Allen CE, Horton T, Jones JY, Vinks AA, McClain KL. Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2009;52(5):621-625.
38. Lee G, Lee SE, Ryu KH, Yoo ES. Posterior reversible encephalopathy syndrome in pediatric patients undergoing treatment for hemophagocytic lymphohistiocytosis: clinical outcomes and putative risk factors. Blood Res. 2013;48(4):258-265.
39. ?Incecik F, Herguner MO, Yildizdas, D, et al. Posterior reversible encephalopathy syndrome due to pulse methylprednisolone therapy in a child. Turk J Pediatr. 2013;55(4):455-457.
40. Morrow SA, Rana R, Lee D, Paul T, Mahon JL. Posterior reversible encephalopathy syndrome due to high dose corticosteroids for an MS relapse. Case Rep Neurol Med. 2015;2015: 325657.
41. Kumar S, Rajam L. Posterior reversible encephalopathy syndrome (PRES/RPLS) during pulse steroid therapy in macrophage activation syndrome. Indian J Pediatr. 2011;78(8): 1002-1004.
42. Balis FM, Lester CM, Chrousos GP, Heideman RL, Poplack DG. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol. 1987;5(2):202-207.
43. Fadeel B, Orrenius S, Henter JI. Induction of apoptosis and caspase activation in cells obtained from familial haemophagocytic lymphohistiocytosis patients. Br J Haematol. 1999;106(2):406-415.
44. Johnson TS, Terrell CE, Millen SH, Katz JD, Hildeman DA, Jordan MB. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol. 2014;192(1): 84-91.
45. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325(24): 1682-1687.
46. Henter JI, Chow CB, Leung CW, Lau YL. Cytotoxic therapy for severe avian influenza A (H5N1) infection. Lancet. 2006;367(9513): 870-873.
47. Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60(1):101-109.
48. De Benedetti F, Brunner HI, Ruperto N, et al; PRINTO; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385-2395.
49. Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154-5157.
50. Das R, Guan P, Sprague L, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 2016;127(13): 1666-1675.
51. Maschalidi S, Sepulveda FE, Garrigue A, Fischer A, de Saint Basile G. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood. 2016;128(1): 60-71.
52. Henter JI, Elinder G, Soder O, Hansson M, Andersson B, Andersson U. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood. 1991;78(11):2918-2922.
53. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD81 T cells and interferon gamma are essential for the disorder. Blood. 2004;104(3):735-743.
54. Pachlopnik Schmid J, Ho CH, Chŕetien F, et al. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforinand Rab27a-deficient mice. EMBO Mol Med. 2009;1(2):112-124.
55. Xu XJ, Tang YM, Song H, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr. 2012;160(6):984-990.e1.
56. Marsh RA, Vaughn G, Kim MO, et al. Reducedintensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010; 116(26):5824-5831.
57. Marsh RA, Kim MO, Liu C, et al. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Biol Blood Marrow Transplant. 2013;19(11):1625-1631.